EpiVax. has been granted a patent for T cell epitopes that include peptide chains from immunoglobulin regions. The patent covers methods for their use and production, specifically detailing a chimeric polypeptide that combines an immunoglobulin fragment with a non-immunoglobulin biologically active molecule. GlobalData’s report on EpiVax gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on EpiVax, Peptide pharmacophores was a key innovation area identified from patents. EpiVax's grant share as of June 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Chimeric polypeptides with immunoglobulin fragments and active molecules
The granted patent US12016909B2 describes a chimeric polypeptide that consists of two linked polypeptide chains. The first chain is a fragment of an immunoglobulin with a specific amino acid sequence (SEQ ID NO: 12), while the second chain comprises a biologically active molecule that is not an immunoglobulin. The claims detail various configurations of the chimeric polypeptide, including the positioning of the second polypeptide chain at either the N-terminus or C-terminus of the first chain. Additionally, the chimeric polypeptide may include isolated T-cell epitope polypeptides from a specified group of sequences, enhancing its potential immunological applications.
The patent further outlines the types of biologically active molecules that can be incorporated into the second polypeptide chain, including viral proteins, bacterial proteins, FVIII molecules, autoimmune antigens, and allergens. A significant aspect of the patent is the method for inducing regulatory T-cells to suppress immune responses in a subject through the administration of the chimeric polypeptide. This method emphasizes the therapeutic potential of the chimeric polypeptide in modulating immune responses, with specific claims regarding the composition and structure of the polypeptide to optimize its efficacy. Overall, the patent presents a novel approach to immunotherapy by leveraging the unique properties of chimeric polypeptides.
To know more about GlobalData’s detailed insights on EpiVax, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
